Premium
Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine
Author(s) -
Bates Theodore R.,
Blumenthal H. Peter,
Pieniaszek Henry J.
Publication year - 1977
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1977226917
Subject(s) - sulfapyridine , sulfasalazine , pharmacokinetics , excretion , pharmacology , medicine , chemistry , ulcerative colitis , disease , organic chemistry
The concentrations of sulJapyridine (SP) and N4‐acetylsulJapyridine (AcSP) in the plasma and saliva of 5 healthy male adults (3 slow and 2 rapid acetylators) were determined as a function of time after a single 2.0‐gm oral dose of sulJasalazine (salicylazosulJapyridine). SP absorption commenced 3.5 to 6 hr after sulJasalazine administration and occurred slowly (apparent absorption tlhs rangedfrom 1.6 to 5 hr) irrespective of acetyl at or phenotype. Appreciable differences existed between slow and rapid acetylators with respect to the biologic tlh and total body clearance of SP. SP concentrations in the saliva correlated well with those in the plasma. The saliva: plasma concentration ratio for SP was 0.559 ± 0.027 (mean of 5 subjects ± SE) and was independent of plasma concentration and saliva pH. The mean saliva: plasma concentration ratio for AcSP was lower (0.246 ± 0.056), consistent with the pH‐partition hypothesis, and showed considerably more intrasubject and intersubject variation than the ratio for SP. These findings suggest that measurement of SP concentrations in the saliva may be a convenient, noninvasive method for monitoring indirectly the steady‐state plasma (serum) concentrations of SP in patients with ulcerative colitis or Crohn's disease who are receiving sulJasalazine.